Menu Search
Equities

Healwell Al Inc

6H90:HAM

Healwell Al Inc

Actions
  • Price (EUR)1.09
  • Today's Change0.05 / 4.83%
  • Shares traded1.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HEALWELL AI Inc. is a Canada-based healthcare technology company focused on artificial intelligence (AI) and data science for preventative care. The Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases. The Company's segments include Medical Clinics, Health Technology and Electronic Health Records. It provides government-insured primary and specialty healthcare through medical clinics, technology-enabled rare disease screening, clinical research, pulmonary function testing lab services, AI-driven healthcare information analytics and insights and subscription-based electronic health record information software. Its products include Khure Health, Pentavere, PolyClinic and WELL AI Decision Support. The Company provides clinical information sources and clinical insights. Its clinical information sources include clinical research and trials, lab and diagnostic info, and semi-structured data.

  • Revenue in CAD (TTM)25.69m
  • Net income in CAD-19.99m
  • Incorporated2020
  • Employees340.00
  • Location
    Healwell Al Inc4881 Yonge Street, Suite 300Toronto M2N5X3CanadaCAN
  • Phone+1 (905) 960-6717
  • Websitehttps://healwell.ai/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AIDX:TOR since
announced		Transaction
value
Intrahealth Systems LtdDeal completed25 Jan 202425 Jan 2024Deal completed127.94%13.76m
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.